Figure 6.

ELISPOT results comparing efficacies of AuNVs using the modified DC-to-splenocyte assays. (A) The DC-to-OT-I splenocyte IFN-γ ELISPOT data comparing the efficacies of the OVA AuNVs and the free peptides. The AuNVs (max dose 10 μg/ml) were able to induce a significantly stronger response than the free peptides (10 μg/ml) (double asterisk denotes p < 0.01). (B) The DC-to-OT-I and pmel-1 splenocyte IFN-γ ELISPOT data comparing the PEG linker AuNVs and the DNA spacer AuNVs for OVA and gp100 (double asterisk denotes p < 0.01; n.s, not significant). (C) The DC-to-OT-I and pmel-1 splenocyte IFN-γ ELISPOT with the OVA and gp100 AuNVs. Each particle responded to its corresponding splenocyte significantly more than the unmatched AuNV (double asterisk denotes p < 0.01).

Lin et al. Nanoscale Research Letters 2013 8:72   doi:10.1186/1556-276X-8-72
Download authors' original image